ArticleDermatology and therapy2025

Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study.

Stephan Weidinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.